Announcements Trials
Browse Landscape

Phase

Phase 2 28Phase 3 7Phase 2/3 6Phase 1/2 4Phase EARLY_PHASE1 3Phase NA 1Phase 4 1

Status

Recruiting 3Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 5OTHER_GOV 1

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 8Gynecologic 6Other 1

Conditions

Endometrial Neoplasms 4Progesterone Resistance 2Endometrial Hyperplasia 2Uterine Neoplasms 1Obesity 1Hydatidiform Mole 1Gestational Trophoblastic Disease 1

Interventions

Paclitaxel 12Carboplatin 11Cisplatin 9Letrozole 6Drug Therapy 6liposomal doxorubicin 5Megestrol Acetate 4Bevacizumab 4spartalizumab 3Topotecan 3Taxes 3Medroxyprogesterone Acetate 3olaparib 2niraparib 2atezolizumab 2Methotrexate 2Magnetic Resonance Spectroscopy 2Imiquimod 2Hyperthermic Intraperitoneal Chemotherapy 2Gonadotropin-Releasing Hormone 2Gemcitabine 2Doxorubicin 21-dodecylpyridoxal 2trametinib 1sintilimab 1saracatinib 1ricin A-GnRH conjugate 1pertuzumab 1pembrolizumab 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2/3 × Letrozole × Gynecologic × Clear all
NCT07319429 2026-03-13

FEMUS

Fudan University

Phase 2/3 Recruiting
260 enrolled
Gynecologic

Endometrial Neoplasms

NCT05454358 2025-12-15

Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP

Fudan University

Phase 2/3 Terminated
12 enrolled
Gynecologic

Endometrial Neoplasms

NCT05316935 2025-08-11

GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

Fudan University

Phase 2/3 Recruiting
80 enrolled
Gynecologic

Progesterone Resistance, Endometrial Hyperplasia, Endometrial Neoplasms

NCT06379113 2025-08-11

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients

Fudan University

Phase 2/3 Recruiting
29 enrolled
GynecologicOther

Progesterone Resistance, Endometrial Hyperplasia, Obesity, Endometrial Neoplasms

NCT05203562 2022-07-12

Letrozole as a Prophylaxis From GTN for Complete Mole Patients

Zagazig University

Phase 2/3 Unknown
200 enrolled
Gynecologic

Hydatidiform Mole, Gestational Trophoblastic Disease

NCT03285802 2020-02-05

Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation

Greater Baltimore Medical Center

Phase 2/3 Completed
1 enrolled
Gynecologic

Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡